ETRADE Capital Management LLC increased its holdings in Allergan plc (NYSE:AGN) by 12.4% during the second quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 36,426 shares of the company’s stock after buying an additional 4,006 shares during the quarter. ETRADE Capital Management LLC’s holdings in Allergan were worth $6,099,000 at the end of the most recent reporting period.
Several other institutional investors and hedge funds have also bought and sold shares of the stock. Motco bought a new stake in shares of Allergan during the second quarter valued at approximately $29,000. Evolution Wealth Advisors LLC bought a new stake in Allergan in the second quarter worth $30,000. Berman Capital Advisors LLC increased its position in Allergan by 48.8% in the first quarter. Berman Capital Advisors LLC now owns 238 shares of the company’s stock worth $34,000 after purchasing an additional 78 shares during the last quarter. Truewealth LLC increased its position in Allergan by 96.8% in the second quarter. Truewealth LLC now owns 248 shares of the company’s stock worth $42,000 after purchasing an additional 122 shares during the last quarter. Finally, Liberty Wealth Management LLC increased its position in Allergan by 35.3% in the second quarter. Liberty Wealth Management LLC now owns 257 shares of the company’s stock worth $43,000 after purchasing an additional 67 shares during the last quarter. 80.86% of the stock is currently owned by institutional investors.
Several equities research analysts recently weighed in on the stock. ValuEngine cut shares of Allergan from a “hold” rating to a “sell” rating in a research report on Tuesday, July 2nd. JPMorgan Chase & Co. set a $200.00 price target on shares of Allergan and gave the stock a “buy” rating in a research report on Wednesday, June 19th. Barclays boosted their price target on shares of Allergan from $176.00 to $188.00 and gave the stock an “equal weight” rating in a research report on Wednesday, August 7th. Guggenheim cut shares of Allergan from a “buy” rating to a “neutral” rating in a research report on Wednesday, August 7th. Finally, UBS Group lifted their price objective on shares of Allergan from $172.00 to $189.00 and gave the stock a “buy” rating in a research note on Thursday. Two analysts have rated the stock with a sell rating, fifteen have assigned a hold rating and seven have given a buy rating to the company’s stock. The company currently has a consensus rating of “Hold” and an average target price of $180.24.
Allergan (NYSE:AGN) last issued its earnings results on Tuesday, August 6th. The company reported $4.38 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $4.34 by $0.04. The firm had revenue of $4.09 billion during the quarter, compared to analyst estimates of $3.93 billion. Allergan had a negative net margin of 54.25% and a positive return on equity of 8.73%. The business’s revenue was down .8% on a year-over-year basis. During the same period in the previous year, the firm earned $4.42 earnings per share. On average, research analysts forecast that Allergan plc will post 16.69 earnings per share for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Friday, September 13th. Investors of record on Tuesday, August 13th will be paid a $0.74 dividend. This represents a $2.96 dividend on an annualized basis and a yield of 1.78%. The ex-dividend date of this dividend is Monday, August 12th. Allergan’s dividend payout ratio (DPR) is presently 17.74%.
Allergan Company Profile
Allergan plc, a pharmaceutical company, develops, manufactures, and commercializes branded pharmaceutical, device, biologic, surgical, and regenerative medicine products worldwide. The company operates in three segments: US Specialized Therapeutics, US General Medicine, and International. It offers a portfolio of products in various therapeutic areas, including medical aesthetics and dermatology, eye care, neuroscience, urology, gastrointestinal, women's health, and anti-infective therapeutic products.
Recommended Story: What is Depreciation?
Want to see what other hedge funds are holding AGN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Allergan plc (NYSE:AGN).
Receive News & Ratings for Allergan Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Allergan and related companies with MarketBeat.com's FREE daily email newsletter.